Biotech company 10x Genomics (NASDAQ: TXG) will be reporting earnings this Thursday after market hours. Here’s what investors should know.

10x Genomics beat analysts’ revenue expectations by 4.6% last quarter, reporting revenues of $149 million, down 1.7% year on year. It was an incredible quarter for the company, with a beat of analysts’ EPS estimates and revenue guidance for next quarter exceeding analysts’ expectations.

Is 10x Genomics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting 10x Genomics’s revenue to decline 3.5% year on year to $159.2 million, improving from the 10.3% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.04 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. 10x Genomics has missed Wall Street’s revenue estimates twice over the last two years.

Looking at 10x Genomics’s peers in the life sciences tools & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Illumina delivered year-on-year revenue growth of 5%, beating analysts’ expectations by 3.2%, and Medpace reported revenues up 32%, topping estimates by 3.3%. Illumina traded down 10.4% following the results while Medpace was also down 16.1%.

Read our full analysis of Illumina’s results here and Medpace’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. 10x Genomics is down 4.5% during the same time and is heading into earnings with an average analyst price target of $18.08 (compared to the current share price of $19.16).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.